This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

ENCORE POSTER
Long-Term Safety and Efficacy of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
Author(s):

Jacob S. Ballon,1 René S. Kahn,2 Martin Dunbar,3 David McDonnell,4 Christoph U. Correll5-7

1 Stanford University, Stanford, CA, USA; 2 Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3 Alkermes, Inc., Waltham, MA, USA; 4 Alkermes Pharma Ireland Ltd., Dublin, Ireland; 5 Zucker Hillside Hospital, Glen Oaks, NY, USA; 6 Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 7 Charité Universitätsmedizin, Berlin, Germany

Content available until 05/28/2026